About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Bayer to Market Biocon Insulin in China

by Medindia Content Team on July 20, 2006 at 7:54 PM
Font : A-A+

Bayer to Market Biocon Insulin in China

Indian biotech major Biocon Ltd has roped in Bayer HealthCare to market its recombinant human insulin Insugen in the Chinese market, the company said in a statement Wednesday.

The Bangalore-based biotech firm plans to launch Insugen in China by 2007-08 after completing the registration trials and seeking the regulatory approvals.

Advertisement

"The marketing tie-up with Bayer will be extended to other countries in the Asia-Pacific region later. The incidence of diabetes is rapidly spreading in China, especially in the urban areas. About 40 million Chinese suffer from diabetes currently, with an estimated 3,000 new cases reported every day," the statement said.

According to Biocon chairperson Kiran Mazumdar-Shaw, Insugen had already achieved critical mass in the Indian market, with substantial market share since its launch.
Advertisement

"The marketing tie-up with Bayer reiterates our commitment to providing biotech solutions to diabetes, termed the 21st century pandemic. We believe Bayer is positioned to achieve significant market share for Insugen in China," Shaw said.

Bayer HealthCare vice-president for Asia Pacific Jean-Luc Lowinski said the agreement with Biocon would strengthen its diabetes franchise strategy and increase its presence in China.

"This deal is the first of its kind in the prescription pharmaceutical market in China. The marketing rights and trademark agreement covers three formulations of insulin: fast-acting (R), intermediate-acting (N), and mixed-acting, in both vials and cartridges," Lowinski pointed out.

The formulations apply to both type-1 and type-2 diabetes. The investment will create a platform for complete diabetes management, with growth potential for Biocon and Bayer in China and other markets, the statement added.

Meanwhile, Biocon reported that it posted a net profit of Rs.390 million for the first quarter (April-June) of the current fiscal (2006-07), the same as in the corresponding quarter of the last fiscal (FY 2006).

In a notification to the stock exchanges, the company said its net income did not appreciate year-on-year YoY) basis due to upfront investments in the biotech park that was recently opened in the electronics city on the outskirts of Bangalore.

The company's consolidated revenue, however, increased by 21 percent to Rs.2.1 billion for the quarter under review (Q1) from Rs.1.8 billion posted in the same quarter a year ago.

The earnings before interest, depreciation, taxes and amortisation (EBIDTA) were Rs.550 million, against Rs.520 million in the same period a year ago.

"Our financial performance in the first quarter has generated good profitability despite challenges. This underpins our confidence in pursuing discovery-led research programs. We believe our innovation led business initiatives have the potential to realise exponential growth in the long-term and deliver superior shareholder value in the future," Shaw said in the statement.

(Source: IANS News)
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Diabetes - Essentials Gestational diabetes Type 2 Diabetes Diabetes - Foot Care Diabesity Diabetes in Pets Diabetes Facts and Figures Insulin Hormone Hypoglycemia (Low Blood Sugar) Insulinoma 

Most Popular on Medindia

Selfie Addiction Calculator Find a Doctor Drug Interaction Checker Nutam (400mg) (Piracetam) Pregnancy Confirmation Calculator A-Z Drug Brands in India How to Reduce School Bag Weight - Simple Tips Loram (2 mg) (Lorazepam) Indian Medical Journals Noscaphene (Noscapine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Bayer to Market Biocon Insulin in China Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests